Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 21 Gastrointestinal 10 NET 9 Genitourinary 4 Breast 3 Thoracic 2 Plasma cell 2 Lymphoid 2 Dermatologic 2 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Head & Neck 1 Gynecologic 1 CNS 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 575 Carboplatin 520 Cisplatin 347 Bevacizumab 252 pembrolizumab 226 Gemcitabine 157 Topotecan 128 liposomal doxorubicin 127 Cyclophosphamide 126 olaparib 120 Taxes 113 Radiotherapy 110 Docetaxel 94 Brachytherapy 89 Doxorubicin 84 Drug Therapy 80 niraparib 75 Nivolumab 71 Magnetic Resonance Spectroscopy 71 Specimen Handling 65 fludarabine 56 Biopsy 55 Hyperthermic Intraperitoneal Chemotherapy 53 Filgrastim 52 Letrozole 50 Oxaliplatin 48 durvalumab 47 Immunoglobulin G 47 atezolizumab 46 Platinum 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × pasireotide × Gynecologic × Clear all

NCT04826432 2024-02-08

PASIREOCHIP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡